Literature DB >> 14702537

Immunosuppression with FK778 and mycophenolate mofetil in a rat cardiac transplantation model.

Tobias Deuse1, Sonja Schrepfer, Hermann Reichenspurner.   

Abstract

FK778 blocks the dihydro-orotate dehydrogenase, necessary for pyrimidine synthesis, and mycophenolate mofetil (MMF) inhibits the inosine monophosphate dehydrogenase, a crucial enzyme for purine biosynthesis. Beneficial immunosuppressive effects have been suggested for the combination of both drugs. The Brown Norway-Lewis rat heterotopic heart transplantation model was used. FK778 (5 and 20 mg/kg/day), MMF (10 and 40 mg/kg/day), or a combination of both drugs for 10 days was used for prevention of acute graft rejection. Grafts of untreated animals were rejected after 6.2 +/- 0.4 days. Low-dose FK778 and low-dose MMF administration did not result in a significantly prolonged graft survival (6.7 +/- 0.8 and 8.7 +/- 1.4 days; P=not significant). Grafts of rats treated with high-dose FK778 or high-dose MMF survived significantly longer (17.0 +/- 2.8 and 20.7 +/- 3.8 days; P<0.01). Concomitant use of low-dose FK778 with low-dose MMF produced synergistic interactions (mean survival time 12.3 +/- 2.9 days; P<0.01; combination index=0.85). High-dose drug combination (mean survival time 24.0 +/- 1.4 days) showed antagonistic drug interaction (combination index=1.55) with increased toxic side effects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14702537     DOI: 10.1097/01.TP.0000092006.43818.B0

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  3 in total

Review 1.  Immunotherapy for De Novo renal transplantation: what's in the pipeline?

Authors:  Helio Tedesco Silva; Paula Pinheiro Machado; Claudia Rosso Felipe; Jose Osmar Medina Pestana
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  The Effects of Administration of Vitamin D, Infliximab, and Leflunomide on Testosterone Concentrations in Rats under Atorvastatin Therapy.

Authors:  Duygun Altintas Aykan; Muhammed Seyithanoglu
Journal:  Eurasian J Med       Date:  2019-10

3.  The Ca²⁺-activated K⁺ channel KCa3.1 as a potential new target for the prevention of allograft vasculopathy.

Authors:  Yi-Je Chen; Jenny Lam; Clare R Gregory; Sonja Schrepfer; Heike Wulff
Journal:  PLoS One       Date:  2013-11-29       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.